500 asthma patients enrolled in landmark biologic registry
NCT ID NCT06456450
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will follow 500 adults in Taiwan who are receiving biologic treatments (such as omalizumab, mepolizumab, or dupilumab) for severe asthma. Researchers aim to see how well these drugs work in everyday practice, what factors predict better control, and how often patients switch treatments. The study does not test a new drug but gathers data to guide future treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taichung Veterans General Hospital
RECRUITINGTaichung, 40705, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- AI and a smartphone app may let kids with asthma skip clinic visits
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Allergy tablets under the tongue may cut hay fever drug use for years, massive real-world study suggests
- Short steroid course after first wheeze may stop asthma before it starts
- New antibody drug aims to tame Hard-to-Control asthma